Detection of myocardial necrosis and inflammation by nuclear cardiac imaging.
For almost two decades, Tc-99m pyrophosphate has been the preferred infarct-avid imaging agent in nuclear cardiology. More recently, Indium-III- and Tc-99m-labeled antimyosin monoclonal antibody imaging have been extensively investigated. Although In-III antimyosin is not yet available in North America, this radioimmunoscintigraphic procedure is very promising for detection of both Q-wave and non-Q-wave myocardial infarction, especially when other standard diagnostic modalities fail to be contributive. When appropriately applied, radionuclide imaging with infarct-avid agents may provide very helpful clinical information.
Taillefer
R
R
Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, Québec, Canada.
D000818:Animals; D000911:Antibodies, Monoclonal; D006801:Humans; D007205:Indium Radioisotopes; D009203:Myocardial Infarction / Q000000981:diagnostic imaging*; D009205:Myocarditis / Q000000981:diagnostic imaging*; D009218:Myosins / Q000276:immunology; D009336:Necrosis; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D011877:Radionuclide Imaging; D016698:Technetium Tc 99m Pyrophosphate
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; C082980:technetium Tc99m-antimyosin; C058899:imciromab pentetate; D016698:Technetium Tc 99m Pyrophosphate; D009218:Myosins